This or a similar approach could potentially inhibit EWS oncogenesis in proliferating EWS cells and EWS stem cells in a way that is analogous to imatinib's action against chronic myelogenous leukemia. This evidence concerns the gene EWSR1 and chronic myelogenous leukemia, BCR-ABL1 positive.